Touchstone
Last syncOct 31, 2026, 6:54 PM ET

TEVA

Teva Pharmaceutical Industries Ltd Health Care Pharmaceutical Preparations Russell 3000
$42.09Close $48.4BMarket cap $20.03 – $42.0952-week range Nov 3, 2026Next report · before the open

Highlights

Strengths

  • In a stage-2 uptrend all 8 trend conditions pass
  • Leading the market RS 90 · stronger than 90% of stocks over 12 months
  • RS line at a 1-year high outperforming the S&P 500 more than at any point this year
  • Near its high at its 52-week high

Cautions

  • Earnings shrinking EPS −304% year on year
  • Results soon Nov 3, 2026, in 2 days
  • Financial distress Altman Z″ in the distress zone

Price

Filing Results Screen pick 52-week high and low Adjusted prices

Key figures

FY to Dec 31, 2025 · filed Jul 29, 2026
Off 12-month high 0%
1wk up 6.8% price change
1mo up 6.3% price change
12-month return up 110% market up 11% · its own up 97%
F-score 8 / 9 Exceptional
Altman Z 1.02 Elevated risk
P/E 34.3× price / earnings
PEG — P/E / EPS growth
P/B 6.1× price / book
Earnings yield up 4.8% EBIT / enterprise value
Cheaper than 45% of the market · around average
Revenue growth up 4% year on year
EPS growth down 304% latest quarter · -373 pts
Sales growth down 1% latest quarter · -3 pts
ROE up 21% return on equity
Free cash margin up 7% $1.1B FCF
D/E — long-term debt / equity
Net debt / EBITDA -1.1× net cash
Interest cover 2.4×EBIT / interest
Piotroski tests
  • issued more shares
  • profitable on its assets
  • generating cash from operations
  • profitability improving
  • profits backed by cash
  • reduced long-term debt
  • short-term liquidity improved
  • gross margin widened
  • assets working harder

Repair signals

  • Gross margin 48.7% → 51.8%

Trade setup

ATR% 2.8% $1.17 a day · 2×ATR $39.75
RS 90 / 99 vs the universe
Trend 8 / 8 trend template
Relative volume 1.3× vs 50-day average
Up/down volume 1.30 50 sessions
Implied move — no option chain · report Nov 3, 2026
Trend template · 8 of 8

Screen verdict

Did not qualify for any screen.

Warning signs

1 flagged
  • Bankruptcy model reads distressed The Altman score sits inside the range historically associated with financial distress. It is used here only to exclude, never to rank, and it is a statistical band rather than a prediction about this company.
Last reported Jul 29, 2026

Financials

6 fiscal years · from filings
Revenue What customers paid the company over its fiscal year, before any cost, as filed in its annual report. The change is against the year before. Methodology $17.3B +4% on FY2024
$0 $20B FY20 FY21 FY22 FY23 FY24 FY25 FY2020 · $16.7B FY2021 · $15.9B FY2022 · $14.9B FY2023 · $15.8B FY2024 · $16.5B FY2025 · $17.3B
Net income Profit left after every cost, interest and tax for the year. A column below the line is a loss. Methodology $1.4B back to a profit
-$5B $0 $2B FY20 FY21 FY22 FY23 FY24 FY25 FY2020 · -$4.0B FY2021 · $417.0M FY2022 · -$2.4B FY2023 · -$559.0M FY2024 · -$1.6B FY2025 · $1.4B
Free cash flow Cash from running the business less what it spent on equipment and buildings: the cash a year actually left behind, which profit alone does not show. Not shown for banks and insurers, whose cash moves with their loans. Methodology $1.1B +53% on FY2024
$0 $2B FY20 FY21 FY22 FY23 FY24 FY25 FY2020 · $638.0M FY2021 · $236.0M FY2022 · $1.0B FY2023 · $842.0M FY2024 · $749.0M FY2025 · $1.1B
Margins Each as a share of revenue. Gross: left after the direct cost of what was sold. Net: left after every cost. Free cash: free cash flow over revenue. A margin rising over years means the business keeps more of each dollar it sells. Methodology
  • Gross 52%
  • Net 8%
  • Free cash 7%
-25% 0% 100% FY20 FY21 FY22 FY23 FY24 FY25 FY2020 · Gross 46% · Net -24% · Free cash 4% FY2021 · Gross 48% · Net 3% · Free cash 1% FY2022 · Gross 47% · Net -16% · Free cash 7% FY2023 · Gross 48% · Net -4% · Free cash 5% FY2024 · Gross 49% · Net -10% · Free cash 5% FY2025 · Gross 52% · Net 8% · Free cash 7%
Cash and long-term debt Cash on the balance sheet at the year's end beside debt due after a year. Net cash is cash less that debt; net debt is the shortfall. Debt some filers do not tag shows as a gap, not as zero. Methodology
  • Cash
  • Long-term debt
$0 $5B FY20 FY21 FY22 FY23 FY24 FY25 FY2020 · Cash $2.2B FY2021 · Cash $2.2B · Long-term debt $40.0M FY2022 · Cash $2.8B FY2023 · Cash $3.2B FY2024 · Cash $3.3B FY2025 · Cash $3.6B
Shares outstanding Shares in issue at the year's end. A rising count means each share owns a smaller slice of the company (stock pay, share sales); a falling one, buybacks. The chart's scale is fitted to the count, so a small change looks large: read the percentage. Methodology 1.15bn +4.9% since FY2020
1.15bn 1.10bn FY20 FY21 FY22 FY23 FY24 FY25 FY2020 · 1.10bn FY2021 · 1.10bn FY2022 · 1.11bn FY2023 · 1.12bn FY2024 · 1.13bn FY2025 · 1.15bn
  FY2020Dec 31, 2020 FY2021Dec 31, 2021 FY2022Dec 31, 2022 FY2023Dec 31, 2023 FY2024Dec 31, 2024 FY2025Dec 31, 2025
Revenue $16.7B $15.9B $14.9B $15.8B $16.5B $17.3B
Gross margin 46% 48% 47% 48% 49% 52%
Operating income -$3.6B $1.7B -$2.2B $433.0M -$303.0M $2.2B
Net income -$4.0B $417.0M -$2.4B -$559.0M -$1.6B $1.4B
Net margin -24% 3% -16% -4% -10% 8%
Earnings per share -$3.64 $0.38 -$2.20 -$0.50 -$1.45 $1.21
Free cash flow $638.0M $236.0M $1.0B $842.0M $749.0M $1.1B
Free cash margin 4% 1% 7% 5% 5% 7%
Cash $2.2B $2.2B $2.8B $3.2B $3.3B $3.6B
Long-term debt — $40.0M — — — —
Shareholders' equity $10.0B $10.3B $7.8B $7.5B $5.4B $7.9B
Shares outstanding 1.10bn 1.10bn 1.11bn 1.12bn 1.13bn 1.15bn

Filings

SEC EDGAR
FiledReportPeriod to Lag
Jul 29, 2026 Quarterly ↗ Jun 30, 2026 29d
Apr 29, 2026 Quarterly ↗ Mar 31, 2026 29d
Feb 3, 2026 Annual ↗ Dec 31, 2025 34d
Nov 5, 2025 Quarterly ↗ Sep 30, 2025 36d
Jul 30, 2025 Quarterly ↗ Jun 30, 2025 30d
May 7, 2025 Quarterly ↗ Mar 31, 2025 37d
Feb 5, 2025 Annual ↗ Dec 31, 2024 36d
Nov 6, 2024 Quarterly ↗ Sep 30, 2024 37d
Jul 31, 2024 Quarterly ↗ Jun 30, 2024 31d
May 8, 2024 Quarterly ↗ Mar 31, 2024 38d
Feb 12, 2024 Annual ↗ Dec 31, 2023 43d
Nov 9, 2023 Quarterly ↗ Sep 30, 2023 40d

Current reports

FiledDisclosed
Oct 29, 2026 Director or officer change ↗
Sep 16, 2026 Material agreement · New obligation ↗
Sep 14, 2026 Other events ↗
Sep 11, 2026 Regulation FD · Other events ↗
Sep 3, 2026 Other events ↗
Sep 3, 2026 Holder rights changed ↗
Jul 29, 2026 Results ↗
May 28, 2026 Shareholder vote ↗
Apr 29, 2026 Results · Regulation FD ↗
Jan 28, 2026 Results ↗
Jan 12, 2026 Results ↗
Dec 11, 2025 Material agreement · New obligation ↗